For example, in the TrialNet Teplizumab Prevention Study, teplizumab-treated participants who were HLA-DR3−/DR4+ had a delay in T1D diagnosis whereas DR3+/DR4− individuals progressed similarly to individuals who received placebo. This evidence concerns the gene TNFRSF10A and type 1 diabetes mellitus.